Is IRadimed Corp. overvalued or undervalued?

As of 13 June 2025, the valuation grade for IRadimed Corp. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a P/E ratio of 39, an EV to EBITDA of 30.68, and a ROCE of 56.93%, which highlight strong operational efficiency despite a relatively high valuation multiple.
In comparison to its peers, IRadimed Corp. has a P/E ratio of 37.26, which is more favorable than Atrion Corp.'s 60.40, suggesting that IRadimed may be a better value proposition. Additionally, its PEG ratio of 3.97 is competitive when compared to the industry average, reinforcing the notion of undervaluation. Notably, IRadimed has outperformed the S&P 500 over various time frames, with a 1-year return of 38.68% compared to the S&P 500's 10.26%, further supporting its attractive valuation narrative.